Skip to main content
Fig. 3 | EJNMMI Research

Fig. 3

From: A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients

Fig. 3

Comparisons of spleen uptake after PET/CT in patients receiving [68Ga]Ga-DOTATATE or [68Ga]Ga-HA-DOTATATE (low and high peptide amounts) showed a significant higher uptake for [68Ga]Ga-DOTATATE compared to [68Ga]Ga-HA-DOTATATE. In addition, peptide amount differences for [68Ga]Ga-HA-DOTATATE did not affect spleen SUVpeak and SUVmax. Lines indicate significant uptake differences between two groups (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001)

Back to article page